Chairman, President, and C.E.O.
Gregory C. Critchfield, M.D., M.S. has served as our Chairman, President and Chief Executive Officer since November 2011. Dr. Critchfield brings decades of experience in the diagnostics industry, including a proven track record of successfully launching diagnostics products and significantly growing revenues for leading diagnostics companies. Previously, Dr. Critchfield was President of Myriad Genetic Laboratories, a wholly-owned subsidiary of Myriad Genetics, Inc., a molecular diagnostics company, from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Dr. Critchfield’s role at Myriad, he served as Senior Vice President, Chief Medical and Science Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Prior to Quest Diagnostics, Dr. Critchfield was the Director of Clinical Pathology at Intermountain Health Care. Dr. Critchfield has served on the boards of Saladax Biomedical Inc., BioTrove Inc., Biocius Life Sciences, Inc., Integrated Diagnostics, Inc., Nodality, Inc., Metamark Genetics, Inc., Lantos Technologies and Condor Therapeutics, Inc., and currently serves as a director of Epic Sciences. He also served as both a reviewer and an NIH Study Section Chair for biomedical computing grants over a period of time encompassing fifteen years. He holds a B.S. in Microbiology from Brigham Young University, an M.S. in Biophysical Sciences from the University of Minnesota and an M.D. from the University of Utah College of Medicine. We believe that Dr. Critchfield’s perspective and experience as our President and Chief Executive Officer, as well as his depth of experience in the diagnostics industry, provide him with the qualifications and skills to serve on our board of directors.
Chief Commercial Officer
Nadia Altomare has more than 20 years of women’s healthcare diagnostics experience. Mrs. Altomare has served as our Chief Commercial Officer since May 2017 and leads the company’s commercialization strategy and execution, accountable for the company’s marketing, public relations, sales, market access, customer service and billing functions. From May 2015 to May 2017, Mrs. Altomare served as President and then CEO and member of the Board of Directors at Abcodia Ltd, an early detection cancer diagnostics company, where she set up the U.S. subsidiary and held full P&L accountability over the global business. Prior to Abcodia, Mrs. Altomare was the Vice President & General Manager of a global DNA analysis business at ThermoFisher Scientific with full P&L accountability. Previously, Mrs. Altomare was the Vice President & General Manager of a cytogenetic DNA business at PerkinElmer. Earlier in her career, Mrs. Altomare held a number of leadership positions through a series of mergers and acquisitions and an IPO, resulting in a company ultimately acquired by PerkinElmer. Among her accomplishments was the startup, build and scale of the ViaCord division. Mrs. Altomare is currently on the Board of Savran Technologies, a private healthcare company focused on enabling the next generation of non-invasive diagnostics. She received an M.B.A from Northeastern University and a B.S. in Business Administration from the State University of New York at Stony Brook.
Incoming Chief Medical Officer
Dr. Michael Foley initially practiced Maternal-Fetal Medicine in private practice for more than 20 years and retires on December 31, 2021 from the role of Chairman of Obstetrics and Gynecology at the University of Arizona College of Medicine Phoenix/Banner Good Samaritan Regional Medical Center, where he served for nearly a decade and now is working with both the university and Sera in an orderly transition that is to be completed at year-end. Dr. Foley received his medical degree from Chicago Medical School in 1984. He completed an Obstetrics and Gynecology residency and a Maternal-Fetal Medicine fellowship at The Ohio State University Hospital in 1988 and 1990, respectively. He is also an award-winning teacher, author, and has published numerous scientific articles while also serving as a reviewer for several medical journals. Dr. Foley is the Lead Editor of Obstetric Intensive Care: A Practical Manual (McGraw-Hill), which is currently in its fifth edition (2018). He is also a Co-editor for Critical Care Obstetrics-Fifth and Sixth Editions (Wiley-Blackstone).
Chief Financial Officer
Jay Moyes has served as our Chief Financial Officer since March 2020. Mr. Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since August 2017. He has been a member of the board of directors of Puma Biotechnology, Inc., a public biotherapeutics company focused on oncology, since April 2012. He has been a member of the board of directors of Biocardia, Inc., a publicly held cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as a member of the board of directors of Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019. Mr. Moyes was a director of Integrated Diagnostics, Inc., a privately held molecular diagnostics company from March 2011 to November 2016. Mr. Moyes was a member of the board of directors of Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017 and Amedica Corporation, a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014, where he was responsible for developing and executing the company’s financial strategy. From May 2008 through July 2009, Mr. Moyes served as the Chief Financial Officer of XDx, Inc. (now CareDx, Inc.), a privately held molecular diagnostics company. In that role, he orchestrated the company’s right-sizing strategy. Prior to that, Mr. Moyes served as the Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007, and as its Vice President of Finance from July 1993 until May 1996, where he led the financial team as it transitioned from a small private company to a publicly held enterprise. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. In that role he established the company’s financial infrastructure. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. At KPMG LLP, he was primarily responsible for conducting financial audits of high-tech and biotech clients. Mr. Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant.
Chief Scientific Officer
John J. Boniface, Ph.D. has served as our Chief Scientific Officer since November 2011. Prior to that, Dr. Boniface briefly served as our Vice President of Research from September 2011 to November 2011. In his role as Chief Scientific Officer, Dr. Boniface is involved with our product development. Dr. Boniface previously served as scientist and program director for multiple biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development, including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals and Eos Biotechnology. Dr. Boniface holds a Ph.D. in Biochemistry from Albany Medical College and a B.S. in Biochemistry from the University of Massachusetts, Amherst. Dr. Boniface was a post-doctoral scholar in the laboratory of Dr. Mark Davis, Department of Microbiology and Immunology, Stanford University School of Medicine.
Chief Data Officer
Dr. Paul Kearney’s passion is working at the intersection of healthcare, data science and innovation where many of the hardest societal and clinical unmet needs can be found and addressed through partnership, data exploration and focused, persistent hard work. Prior to joining Sera Prognostics, Dr. Kearney co-founded multiple successful biotech companies resulting in the development and commercialization of breakthrough products in the disease areas of oncology, pregnancy and food allergy as well as technological products in bioinformatics and proteomics. Dr. Kearney has extensive experience building and nurturing integrated teams, conducting clinical research, developing evidence for improved health outcomes as well as fund raising. Dr. Kearney has published over 100 papers in diverse areas and awarded over 12 patents. Past experiences include the Institute for Systems Biology, Integrated Diagnostics, Caprion (now CellCarta), Data Incites, Bioinformatics Solutions, AllerGenis as well as a member of the Computer Science Faculty of the University of Waterloo. He received his Ph.D. from the University of Toronto.
Chief Business Officer
Douglas Fisher, M.D. has served as our Chief Business Officer since January 2015. In his role as Chief Business Officer, Dr. Fisher manages our business and strategy development. Dr. Fisher served as a member of our board of directors from November 2011 to January of 2015. In addition to his employment with our company, Dr. Fisher is also an Executive in Residence at InterWest Partners LLC, a venture capital firm and our affiliate. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm. Dr. Fisher currently serves on the board of private companies Boston Microfluidics, Inc., Gynesonics, Inc., Indi Molecular, Inc, Imagine Scientific, Inc. and Lycera, Inc. and public companies Precipio Diagnostics and Obalon Therapeutics, Inc. Dr. Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania.
Vice President of Clinical Sciences
Thomas Garite has served as our Vice President of Clinical Science since June 2020. In his role as Vice President of Clinical Science, Dr. Garite directs all clinical research and related activities. Since February, 2013, Dr. Garite also has served as the Chief Clinical Officer, a consulting role, at Perigen, Inc., a national patient safety company. From January 2001 to June 2020, Dr. Garite served as Director of Research and Education for Obstetrix at MedNax Medical Group, where he directed a collaborative research group composed of a consortium of private practices and university maternal-fetal medicine group. Under his leadership, his team published 25 collaborative studies including 10 multicenter collaborative research trials all in high-impact obstetric journals during his 18-year tenure with the company. Dr. Garite recently retired from his position as Edward H. Quilligan Professor of Obstetrics and Gynecology at the University of California at Irvine. Dr. Garite served 18 years as this Department’s Chairman, and now holds the title of Professor Emeritus. He is also the past Editor in Chief of the American Journal of Obstetricians and Gynecology and remains Editor Emeritus. Dr. Garite has published more than 200 articles and chapters, including over 150 original peer-reviewed journal articles and is the author or co-author of five textbooks. His research has focused on intrapartum and antepartum fetal assessment through fetal heart rate monitoring, prematurity in general, premature rupture of membranes, the infectious etiology of prematurity, and the management of labor. Dr. Garite holds an M.D. from the University of California Irvine College of Medicine and attended California State University, Northridge for undergraduate studies.
Chief Information Officer
For more than three decades, Rob Harrison has served in several senior leadership positions of both public and private companies. His most recent appointment has been with Myriad Genetics, Inc. (NASDAQ: MYGN) as Chief Information Office Officer, where he architected the IT infrastructure that enabled Myriad to grow from its first product launch in 1996 with fewer than 100 employees in a single location, to become a leading global precision medicine company, with multiple products, more than 2,700 employees and deploying testing facilities and services in three continents. Rob successfully directed the IT integration of strategic acquisitions of four companies, simultaneously facilitating international business expansion over the past decade in the company’s growth. Serving as a long-standing board member of the Utah Technology Council, Mr. Harrison remains an active member of the Association for Information Management (AIM) Utah CIO Council, and is also a respected community leader committed to charitable causes that benefit the well-being of women.
Benjamin G. Jackson has served as our General Counsel since April 2021. From February 2006 to March 2021, Mr. Jackson was employed by Myriad Genetics, most recently serving as Executive Vice President, General Counsel and Secretary. Mr. Jackson held various positions in Myriad’s Legal Department, including serving as associate general counsel prior to assuming the role of general counsel. Mr. Jackson received his J.D. from the J. Reuben Clark Law School at Brigham Young University and a B.S. in microbiology, immunology and molecular genetics from the University of California, Los Angeles.
Vice President of Quality/Regulatory and HIPAA Privacy Officer
Nichole L. Martin has served as our Vice President of Quality/Regulatory and HIPAA Privacy Officer, since May 2020. In her role as Vice President of Quality/Regulatory and HIPAA Privacy Officer, Ms. Martin oversees all quality assurance and regulatory activities within Sera, including the CAP/CLIA laboratory and regulated activities throughout the company. She works very closely with the heads of all departments to ensure the highest quality results delivery and compliance with applicable regulations. She is also responsible for development and monitoring of quality improvement initiatives, quality metrics, quality systems, regulatory reporting and communication as well as all regulatory aspects of study design. Ms. Martin holds a number of certifications from the American Society for Quality and the Regulatory Affairs Professionals Society. Previously, Ms. Martin served as Senior Director, Quality Management at Progenity, Inc., from June 2018 to May 2020, and as Quality Director, U.S. Head of Quality at Oxford Immunotec from December 2015 to May 2018 (Oxford Immunotec has since been acquired by Quest Diagnostics and PerkinElmer, Inc.). From 2008 to 2015, Ms. Martin served as Quality Director, Americas at Q Solutions. Ms. Martin occasionally serves as a part-time consultant at Client Confidential in an ad-hoc capacity. Ms. Martin holds an M.S. in Quality Assurance, Manufacturing from California State University and a B.S. in Biochemistry and a minor in Genetics from North Carolina State University.
Senior Vice President of Laboratory Operations
John M. Peltier, Ph.D. has served as our Senior Vice President of Laboratory Operations since August 2016. In his role as Senior Vice President of Laboratory Operations, Dr. Peltier manages the Sera Clinical Laboratory. Dr. Peltier previously served as Laboratory Head and Senior Investigator at Novartis Institutes for Biomedical Research from August 2009 to August 2016. Prior to that, Dr. Peltier served as Senior Director, Spectrometry at Correlogic Systems, Inc. from April 2007 to July 2009, and as Director of Drug metabolism and Pharmacokinetics (DMPK) and Discovery Analytical Sciences at Prolexys Pharmaceuticals, from December 2001 to March 2007. Dr. Peltier holds a Ph.D. in Chemistry from McMaster University and a B.Sc. in Chemistry from McMaster University.